Skip to content

BRING-UP Prevention

BRING-UP Prevention

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06275113
Enrollment
6000
Registered
2024-02-23
Start date
2023-09-15
Completion date
2026-06-30
Last updated
2024-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Disorders, Ischemic Heart Disease, Peripheral Arterial Disease

Brief summary

The aim of this observational study is to assess in patients with a documented athero-thrombotic event: coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD): * the level of adherence to guideline recommendations with the assumption to improve the rate of patients at goal for cholesterol levels. * the level of adherence to guideline recommendations and the rate of patients at goal for the other relevant and modifiable risk factors for cardiovascular event recurrence.

Detailed description

Observational, prospective, multicenter study conducted in a large, representative sample of Italian cardiology centers. Phases: 1. First educational intervention to discuss the recommendations of guidelines for secondary prevention strategies. 2. Data collection for 3 months or up to 30 consecutive patients in patients with documented CAD/CVD/PAD on a web Case Record Form (CRF) generating warning on the most relevant guideline recommendations, and, when guidelines are not followed, asking the reason for non-adherence. 3. Evaluation of the primary and secondary end-points of the study at 6 months after enrollment. 4. Second educational intervention to share the results of the first enrollment period of the study focusing the attention on existing gaps between guidelines recommendations and clinical practice. 5. New data collection for 3 months or up to 30 consecutive patients in patients with documented CAD/CVD/PAD on a web CRF generating warning on the most relevant guideline recommendations, and, when guidelines are not followed, asking the reason for non-adherence. 6. Additional evaluation of the primary and secondary end-points of the study at 6 months after enrollment. 7. 12-month follow-up for all patients included in both enrolment phases.

Interventions

None listed

Sponsors

Heart Care Foundation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Both sexes at birth, age ≥18 years At least one of the following clinical conditions: * Documented CAD defined as: * Prior Acute Coronary Syndrom (ACS) * Prior Coronary Artery Bypass Graft (CABG) * Prior Percutaneous Coronary Intervention (PCI) * Documented PAD (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease, Ankle Brachial Index (ABI)\<90). * Documented CVD: Ischemic stroke, previous carotid vascular interventions. * Signed informed consent.

Exclusion criteria

* Active neoplasia or very severe disease compromising short-medium term life expectancy. * Participation in interventional studies. * Patients already enrolled into the study from another participating center or in the previous enrolling phase.

Design outcomes

Primary

MeasureTime frameDescription
Adherence to guideline for cholesterol level6 monthsRate of patients at goal for LDL cholesterol (\<55 mg/dL)

Secondary

MeasureTime frameDescription
Adherence to guideline for other risk factors6 monthsRate of patients at goal for BP (SBP/DBP \< 130/80 mmHg) and at goal for HbA1c (\<7%) as well as rate of overweight patients (BMI \> 27 kg/m2) who show a weight loss of at least 10%

Other

MeasureTime frameDescription
Patients' outcome12 monthsRate of occurrence of clinical events (all-cause deaths, recurrent athero-thrombotic events, all cause hospitalizations, specific causes of death and hospitalizations) during the 12 follow-up of each enrolment phase.

Countries

Italy

Contacts

Primary ContactFurio Colivicchi, MD
bringup.prevenzione@heartcarefoundation.it055/5101361
Backup ContactAldo P Maggioni, MD
maggioni@heartcarefoundation.it055/5101361

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026